Search PubMed⌕ Search

Biomedical subjects

N Chisholm

Publications and source records attributed to N Chisholm.

8 recordsLinked to original sources

Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.

In order to assess the immunogenicity of a two-dose regimen of Haemophilus influenzae type b polysaccharide vaccine, the immune response to vaccine given at both 18 and 24 months of age was compared to the response to a single dose at 24 months of age. Following immunization at 24 months of age, the geometric mean antibody concentration of children previously immunized at 18 months (0.53 micrograms/ml) was significantly lower than that of children who received a single dose of vaccine at 24 months (1.03 micrograms/ml; p = 0.03). A four-fold rise in antibody concentration was demonstrated in 31% of children who had received two immunizations and 53% of children immunized for the first time at 24 months of age (p = 0.02). These results suggest that the administration of a dose of plain polysaccharide vaccine at 18 months of age blunted the response to reimmunization at 24 months of age. A subgroup of children who failed to respond to one or two doses of plain polysaccharide vaccine were immunized with polysaccharide-diphtheria toxoid conjugate vaccine. The majority of these children developed a significant rise in antibody concentration in response to conjugate vaccine.

Age Factors↗

Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program.

An enhanced pertussis surveillance and laboratory diagnosis program was initiated in the Halifax metropolitan area of Nova Scotia to better delineate the epidemiology of pertussis. During the 28 months of the study, 526 cases of pertussis were identified (overall yearly incidence: 74 cases per 100,000 population). Laboratory confirmation was obtained in 168 (32%) cases, including 111 (21%) by culture. Peak incidence occurred among children 2 to 5 years of age; the highest morbidity rate was seen in children less than 1 year of age. Hospitalization was required for 22 (4.2%) patients; 14 (64%) of those hospitalized were less than 1 year of age. Most (91%) patients had received at least three doses of pertussis vaccine; vaccine efficacy was estimated at 45%. The surveillance program demonstrated that the incidence of pertussis in Nova Scotia, although among the highest in North America, is still underestimated. A ninefold increase in cases was identified over the comparable period of the previous year, largely because patients meeting clinical criteria were reported. By supplementing culture techniques with immunofluorescent staining and serologic methods, we increased the rate of laboratory confirmation from 17% to 65%, suggesting that strict clinical criteria accurately reflect accurately reflect incidence. We conclude that pertussis remains a significant health problem in Nova Scotia, despite nearly universal vaccination.

Child, Preschool↗